View Future GrowthAvalyn Pharma 過去の業績過去 基準チェック /06Avalyn Pharmaの収益は年平均-61.7%で減少しているが、Pharmaceuticals業界はgrowingで10.7%年平均の収益となった。主要情報-61.69%収益成長率51.25%EPS成長率Pharmaceuticals 業界の成長5.95%収益成長率n/a株主資本利益率-87.58%ネット・マージンn/a前回の決算情報31 Mar 2026最近の業績更新更新なしすべての更新を表示Recent updatesライブニュース • Jun 18Avalyn Pharma Stock in Focus as Phase 2b MIST Trial Hits Patient Enrollment Goal EarlyAvalyn Pharma has completed target enrollment of 375 patients in its Phase 2b MIST trial evaluating AP01, an inhaled form of pirfenidone, for progressive pulmonary fibrosis (PPF). The MIST trial reached full enrollment ahead of schedule, indicating strong demand from patients and clinicians for additional treatment options in PPF. Avalyn expects to report topline 12‑month clinical results from the MIST trial in the second half of 2027. Completion of enrollment in this key Phase 2b study marks an important clinical milestone for Avalyn Pharma, as it moves AP01 further along the development path for patients with progressive pulmonary fibrosis. Investors will likely focus on the eventual MIST readout timing and any interim updates, while also considering the usual clinical, regulatory, and funding risks that apply to late-stage drug development.お知らせ • Jun 17Avalyn Pharma Inc. Completes Target Enrollment In Phase 2b MIST Trial Of AP01 For Patients With Progressive Pulmonary FibrosisAvalyn Pharma Inc. completed target enrollment of 375 patients in the Phase 2b MIST clinical trial of AP01 (inhaled pirfenidone) in patients with progressive pulmonary fibrosis (PPF). Additional patients currently in screening remain eligible for randomization and may be enrolled in the trial over the next several weeks. MIST is a global, randomized, double-blinded, placebo-controlled Phase 2b clinical trial evaluating the safety and efficacy of two doses of AP01 in patients with PPF. MIST was designed to enroll 375 patients with PPF, randomized 2:1:2 into three cohorts: AP01 100 mg twice-daily, AP01 50 mg twice-daily, and placebo. The primary endpoint is the change from baseline in lung function, as measured by forced vital capacity (FVC), at 52 weeks. Based on data from the ATLAS Phase 1b trial and ongoing open-label extension study, AP01’s tolerability profile may enable patients to remain on treatment longer. AP01 is an optimized formulation of pirfenidone administered using the PARI eRapid Nebulizer System. AP01 is currently in clinical development for the treatment of progressive pulmonary fibrosis. In the ATLAS Phase 1b study comparing 100 mg twice-daily and 50 mg once-daily doses of AP01, results showed low rates of side effects, including gastrointestinal toxicities and liver enzyme elevations, and suggested a trend toward stability in lung function at the higher dose. AP01 is currently being evaluated in the MIST Phase 2b trial in patients with PPF.ライブニュース • Jun 04Avalyn Pharma Advances Mid-Stage Lung Trials With US$345 Million IPO FundingAvalyn reported first quarter 2026 results and highlighted progress across its inhaled fibrosis programs. The MIST Phase 2b trial of lead candidate AP01 in progressive pulmonary fibrosis is expected to complete enrollment in mid-2026, supported by favorable long-term clinical data. Enrollment is ongoing in the AURA Phase 2 trial of AP02 in idiopathic pulmonary fibrosis, with topline data planned by the end of 2027, and the company recently completed an upsized IPO raising about US$345.0 million to fund operations through 2029. The key takeaway is that Avalyn is now well funded for several years while it advances two mid-stage clinical trials targeting serious lung diseases. Investors should keep in mind that clinical and regulatory outcomes for AP01 and AP02 remain central risks, since Avalyn’s current value is closely tied to trial progress and eventual approval prospects.お知らせ • May 01Avalyn Pharma Inc. has completed an IPO in the amount of $300.000006 million.Avalyn Pharma Inc. has completed an IPO in the amount of $300.000006 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 16,666,667 Price\Range: $18 Discount Per Security: $1.26 Transaction Features: Sponsor Backed Offering収支内訳Avalyn Pharma の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史NasdaqGS:AVLN 収益、費用、利益 ( )USD Millions日付収益収益G+A経費研究開発費31 Mar 260-95168431 Dec 250-851577質の高い収益: AVLNは現在利益が出ていません。利益率の向上: AVLNは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: AVLNは株式公開されてから 3 年未満しか経っていないため、過去 5 年間の前年比収益成長率がプラスであったかどうかを判断できません。成長の加速: AVLNの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: AVLNは利益が出ていないため、過去 1 年間の収益成長をPharmaceuticals業界 ( -4.8% ) と比較することは困難です。株主資本利益率高いROE: AVLNは現在利益が出ていないため、自己資本利益率 ( -87.58% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/06 07:40終値2026/07/06 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Avalyn Pharma Inc. 3 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。4 アナリスト機関Gavin Clark-GartnerEvercore ISISeamus FernandezGuggenheim Securities, LLCRoger SongJefferies LLC1 その他のアナリストを表示
ライブニュース • Jun 18Avalyn Pharma Stock in Focus as Phase 2b MIST Trial Hits Patient Enrollment Goal EarlyAvalyn Pharma has completed target enrollment of 375 patients in its Phase 2b MIST trial evaluating AP01, an inhaled form of pirfenidone, for progressive pulmonary fibrosis (PPF). The MIST trial reached full enrollment ahead of schedule, indicating strong demand from patients and clinicians for additional treatment options in PPF. Avalyn expects to report topline 12‑month clinical results from the MIST trial in the second half of 2027. Completion of enrollment in this key Phase 2b study marks an important clinical milestone for Avalyn Pharma, as it moves AP01 further along the development path for patients with progressive pulmonary fibrosis. Investors will likely focus on the eventual MIST readout timing and any interim updates, while also considering the usual clinical, regulatory, and funding risks that apply to late-stage drug development.
お知らせ • Jun 17Avalyn Pharma Inc. Completes Target Enrollment In Phase 2b MIST Trial Of AP01 For Patients With Progressive Pulmonary FibrosisAvalyn Pharma Inc. completed target enrollment of 375 patients in the Phase 2b MIST clinical trial of AP01 (inhaled pirfenidone) in patients with progressive pulmonary fibrosis (PPF). Additional patients currently in screening remain eligible for randomization and may be enrolled in the trial over the next several weeks. MIST is a global, randomized, double-blinded, placebo-controlled Phase 2b clinical trial evaluating the safety and efficacy of two doses of AP01 in patients with PPF. MIST was designed to enroll 375 patients with PPF, randomized 2:1:2 into three cohorts: AP01 100 mg twice-daily, AP01 50 mg twice-daily, and placebo. The primary endpoint is the change from baseline in lung function, as measured by forced vital capacity (FVC), at 52 weeks. Based on data from the ATLAS Phase 1b trial and ongoing open-label extension study, AP01’s tolerability profile may enable patients to remain on treatment longer. AP01 is an optimized formulation of pirfenidone administered using the PARI eRapid Nebulizer System. AP01 is currently in clinical development for the treatment of progressive pulmonary fibrosis. In the ATLAS Phase 1b study comparing 100 mg twice-daily and 50 mg once-daily doses of AP01, results showed low rates of side effects, including gastrointestinal toxicities and liver enzyme elevations, and suggested a trend toward stability in lung function at the higher dose. AP01 is currently being evaluated in the MIST Phase 2b trial in patients with PPF.
ライブニュース • Jun 04Avalyn Pharma Advances Mid-Stage Lung Trials With US$345 Million IPO FundingAvalyn reported first quarter 2026 results and highlighted progress across its inhaled fibrosis programs. The MIST Phase 2b trial of lead candidate AP01 in progressive pulmonary fibrosis is expected to complete enrollment in mid-2026, supported by favorable long-term clinical data. Enrollment is ongoing in the AURA Phase 2 trial of AP02 in idiopathic pulmonary fibrosis, with topline data planned by the end of 2027, and the company recently completed an upsized IPO raising about US$345.0 million to fund operations through 2029. The key takeaway is that Avalyn is now well funded for several years while it advances two mid-stage clinical trials targeting serious lung diseases. Investors should keep in mind that clinical and regulatory outcomes for AP01 and AP02 remain central risks, since Avalyn’s current value is closely tied to trial progress and eventual approval prospects.
お知らせ • May 01Avalyn Pharma Inc. has completed an IPO in the amount of $300.000006 million.Avalyn Pharma Inc. has completed an IPO in the amount of $300.000006 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 16,666,667 Price\Range: $18 Discount Per Security: $1.26 Transaction Features: Sponsor Backed Offering